Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8922-8929

  Sun, Jiazhi ^a,b,d   Ohkanda, Junko ^c   Coppola, Domenico ^b   Yin, Hang ^c   Kothare, Mohit ^c   Busciglio, Brian ^a,b   Hamilton, Andrew D ^c   Sebti, Saïd M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c YALE UNIVERSITY   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELL PROTEIN; ENZYME INHIBITOR; FTI 2148; GERANIOL; GERANYLGERANYLTRANSFERASE I INHIBITOR; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; GGTI 2154; GGTI-2154; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN; HSDJ PROTEIN; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN R RAS; R RAS PROTEIN; R-RAS PROTEIN; RAP PROTEIN; RAP1 PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; GROWTH INHIBITION; IN VIVO STUDY; INHIBITION KINETICS; METABOLISM; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NECROSIS; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PATHOLOGY; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; GENES, RAS; GTP PHOSPHOHYDROLASES; HEAT-SHOCK PROTEINS; HSP40 HEAT-SHOCK PROTEINS; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NECROSIS; RAP1 GTP-BINDING PROTEINS; RAS PROTEINS; RHOA GTP-BINDING PROTEIN;

EID: 0347320784     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.
2. Zohn, I. M., Campbell, S. L., Khosravi-Far, R., Rossman, K. L., and Der, C. J. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene, 17: 1415-1438, 1998.
3. Zhang, F. L., and Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem., 65: 241-269, 1996.
4. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
5. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., and Pai, J. K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
6. Lerner, E. C., Qian, Y., Hamilton, A. D., and Sebti, S. M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem., 270: 26770-26773, 1995.
7. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 16: 1467-1473, 1998.
8. James, G. L., Goldstein, J. L., and Brown, M. S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
9. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene, 19: 6584-6593, 2000.
10. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin. Investig, Drugs, 9: 2767-2782, 2000.
11. Gibbs, J. B., and Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37: 143-166, 1997.
12. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
13. Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., and Sebti, S. M. Antitumor efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res., 59: 4919-4926, 1999.
14. Vogt, A., Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J. Biol. Chem., 272: 27224-27229, 1997.
15. Adnane, J., Bizouarn, F. A., Qian, Y., Hamilton, A. D., and Sebti, S. M. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol. Cell. Biol., 18: 6962-6970, 1998.
16. Ashar, H. R., James, L., Gray, K., Carr, D., McGuirk, M., Maxwell, E., Black, S., Armstrong, L., Doll, R. J., Taveras, A. G., Bishop, W. R., and Kirschmeier, P. The farnesyl transferase inhibitor SCH 66336 induces a G(2) → M or G(1) pause in sensitive human tumor cell lines. Exp. Cell Res., 262: 17-27, 2001.
17. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W., and Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 61: 131-137, 2001.
18. Crespo, N. C., Ohkanda, J., Yen, T. J., Hamilton, A. D., and Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem., 276: 16161-16167, 2001.
19. Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., and Cheng, J. Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol., 20: 139-148, 2000.
20. Du, W., Liu, A., and Prendergast, G. C. Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res., 59: 4208-4212, 1999.
21. Sun, J., Qian. Y., Chen, Z., Marfurt, J., Hamilton, A. D., and Sebti, S. M. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem., 274: 6930-6934, 1999.
22. Adjei, A. A. Farnesyltransferase inhibitors. Cancer Chemother. Biol. Response Modif., 20: 151-167, 2002.
23. Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., and End, D. W. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol., 13: 470-476, 2001.
24. Gibbs, J. B., Graham, S. L., Hartman, G. D., Koblan, K. S., Kohl, N. E., Omer, C. A., Pellicier, A., Windle, J. J., and Oliff, A. Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice. In: S. M. Sebti and A. D. Hamilton (eds.), Farnesyltransferase Inhibitors in Cancer Therapy, pp. 65-70. Totowa, NJ: Humana Press, 2001.
25. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
26. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
27. Norgaard, P., Law, B., Joseph, H., Page, D. L., Shyr, Y., Mays, D., Pietenpol, J. A., Kohl, N. E., Oliff, A., Coffey, R. J., Jr., Poulsen, H. S., and Moses, H. L. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res., 5: 35-42, 1999.
28. Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., Davide, J. P., Ellis. M. S., Gibbs, J. B., Greenberg, I., Koblan, K. S., Kral, A. M., Liu, D., Lobell, R. B., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Senderak, E. T., Oliff, A., and Kohl, N. E. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res., 60: 2680-2688, 2000.
29. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
30. Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., and Leder, P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell, 49: 465-475, 1987.
31. Terada, K., and Mori, M. Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70. J. Biol. Chem., 275: 24728-24734, 2000.
32. Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A., and Kaufmann, S. H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res., 6: 2318-2325, 2000.
33. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
34. Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A., Davide, J. P., deSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M. S., Kral, A. M., Liu, D., Lumma, W. C., Machotka, S. V., Rands, E., Williams, T. M., Graham, S. L., Hartman, G. D., Oliff, A. I., Heimbrook, D. C., and Kohl, N. E. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res., 61: 8758-8768, 2001.
35. Cox, A. D., and Der, C. J. Ras family signaling: therapeutic targeting. Cancer Biol. Ther., 1: 599-606, 2002.
36. Aapro, M. S. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist, 6: 376-385, 2001.
37. Lundin, J., Lundin, M., Holli, K., Kataja, V., Elomaa, L., Pylkkanen, L., Turpeenniemi-Hujanen, T., and Joensuu, H. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer; results from a nationwide study. J. Clin. Oncol., 19: 28-36, 2001.